Turmeric (Curcumin): Traditional Use, Constituents and Evidence

Forty-seven peer-reviewed trials. One molecule. And a bioavailability problem so persistent it has frustrated researchers for decades. That's roughly where curcumin research sits right now, and it's a more honest picture than most wellness coverage gives you.

I've grown Curcuma longa in a pot on a north-facing step near Stirling for three seasons. It never quite reaches the rhizome mass you'd get in tropical Queensland, but the foliage alone is worth it. My nan called turmeric "the yellow ginger" and added it to everything , rice, warm milk, a paste she'd press onto whatever needed pressing. She had no idea she was working with a polyphenol that would eventually generate more clinical literature than almost any other plant-derived compound. Funny how that goes.

Traditional and historical use

Curcuma longa (family Zingiberaceae) is native to South and Southeast Asia, and its underground rhizome has been used in Ayurvedic and Traditional Chinese medicine for at least 4,000 years. Sanskrit texts document it under the name haridra. In Ayurveda, turmeric featured in formulations addressing digestion, skin and respiratory function, classified broadly as a rasayana , a restorative category of herbs.

Across South Asian culinary traditions, the fresh or dried rhizome is inseparable from daily cooking. In West Africa and the Caribbean, related Curcuma species filled similar cultural roles. European botanical interest arrived relatively late; turmeric appears in 16th-century European herbals mostly as a curiosity, described as "Indian saffron" and noted primarily as a textile dye. It was the colonial spice trade, not European medicine, that brought it westward at scale.

As a phytomedicine, turmeric sits within a long tradition of whole-rhizome preparations rather than isolated constituents. That distinction matters , a lot; when interpreting modern research, as I'll come back to.

Key chemical constituents

The dried rhizome contains somewhere between 2% and 9% curcuminoids by weight, depending on variety, growing conditions and drying method. Three curcuminoids dominate:

• Curcumin (diferuloylmethane), typically 77% of the curcuminoid fraction; the most studied and the one most formulations are standardised to.
• Demethoxycurcumin, roughly 17%; structurally similar with one fewer methoxy group.
• Bisdemethoxycurcumin; about 3-5%; the least lipophilic of the three.

Beyond curcuminoids, the rhizome contains an essential oil fraction (roughly 3-7%) that includes ar-turmerone, turmerone and zingiberene. These volatile constituents share chemical territory with the terpene class, specifically sesquiterpenes, which appear in the essential oil fraction of many botanicals, including hemp. Whether the whole-rhizome terpene matrix influences how curcuminoids behave in the body is an open question in the literature; some researchers suspect it does, though evidence is thin so far.

Curcumin is a bis-α,β-unsaturated β-diketone. That structure is responsible for its vivid yellow-orange colour; and for its notorious chemical instability. In alkaline aqueous environments, curcumin degrades rapidly. This creates obvious complications for oral formulations, and it goes some way to explaining why in vitro (cell culture) studies so regularly fail to translate to comparable human results.

The bioavailability problem

This is, honestly, the most important thing to understand about curcumin research. Raw curcumin is poorly absorbed from the gastrointestinal tract, undergoes rapid metabolism, and is quickly eliminated. First-pass metabolism in the liver converts it to glucuronide and sulfate conjugates with low biological activity. Blood plasma levels after a standard oral dose are vanishingly small.

Researchers have spent considerable effort engineering around this. The classic approach is co-administration with piperine, an alkaloid from black pepper (Piper nigrum), which inhibits glucuronidation and has been shown in one widely cited 1998 study (Shoba et al., published in Planta Medica) to increase curcumin bioavailability by up to 2,000% in human subjects. Lipid-based formulations, nanoparticle encapsulation, phospholipid complexes and micellar preparations have all been explored as alternatives. Some show promise in pharmacokinetics studies; few have been tested at scale in long-term human trials.

Any product label referencing a standardised extract should specify which curcuminoid fraction it is standardised to, and what delivery technology (if any) is employed to address absorption. Without that information, the listed curcumin percentage tells you relatively little about what the body will actually receive. Our glossary entry on bioavailability covers the general principles here in more detail.

What the research actually shows, and where it falls short

Preclinical (cell and animal) research has examined curcumin across a wide range of biological pathways. Laboratory studies have characterised its interactions with NF-κB signalling, COX-2 expression, and various oxidative stress markers. These are mechanistic findings, they describe how curcumin behaves in controlled laboratory settings, not in living humans dealing with a health condition.

Human clinical trials exist, but the picture is complicated. A 2017 systematic review by Nelson and colleagues published in the Journal of Medicinal Chemistry attracted significant attention for arguing that curcumin is, in medicinal chemistry terms, a "pan-assay interference compound" (PAINS); a molecule prone to producing false-positive signals in screening assays, which may have inflated the apparent promise of early research. This view is not universally accepted; others argue the PAINS classification does not fully account for curcumin's genuine in vivo activity. But it's worth knowing the debate exists.

Clinical trials in humans remain relatively small, often short in duration, heterogeneous in formulation (different curcuminoid percentages, different delivery systems), and not always adequately blinded. Meta-analyses attempting to pool this data encounter significant methodological inconsistency. The short version is: the mechanistic hypotheses are genuinely interesting, and the human evidence base is not yet strong enough to draw firm conclusions about clinical outcomes. That doesn't mean the research should be dismissed, it means it needs more rigorous, large-scale work.

I'd argue that some corners of the wellness industry have moved decades ahead of where the human trial evidence actually sits. That's not unique to curcumin, but it's particularly visible here given the volume of products on the market.

Regulatory status in Australia

In Australia, turmeric and curcumin products fall under the Therapeutic Goods Administration's complementary medicines framework. Most are listed medicines on the Australian Register of Therapeutic Goods (ARTG), meaning the TGA has assessed them for safety, quality and manufacturing compliance under Good Manufacturing Practice standards, but has not independently evaluated the clinical evidence for their specific indications.

Listed medicines (ARTG "L" numbers) may carry only low-level, pre-approved indication statements drawn from the TGA's permitted indications list. They cannot make therapeutic claims that go beyond what the Therapeutic Goods Act 1989 and the associated advertising code permit. Statements implying that a listed curcumin product treats, manages or cures a specific named condition would represent a regulatory breach. Consumers are entitled to look up any product's ARTG listing at the TGA's public database to verify its status.

There are no import restrictions on turmeric as a food ingredient or on curcumin in standard listed-medicine presentations; this distinguishes it from some other traditional botanicals with more complicated regulatory histories in Australia (kava, for instance, is subject to specific Commonwealth import controls under the Customs (Prohibited Imports) Regulations 1956 and biosecurity-related provisions, with a tightly regulated personal importation scheme). Curcumin sits in much more open regulatory territory.

If a curcumin formulation were to make claims reaching beyond listed-medicine indications, say, claims about treating a serious disease, it would need to be registered (an "R" product) and would require substantiated clinical evidence to the TGA's satisfaction. That is a substantially higher evidentiary bar. Worth knowing if you encounter products that seem to promise a great deal.

Whole rhizome versus isolated curcumin

One of the more interesting tensions in this field is between the traditional-use model; whole dried rhizome, used in gram-scale culinary quantities over a lifetime, and the research model, which almost exclusively focuses on isolated or semi-purified curcuminoid fractions administered at doses far exceeding culinary use.

The idea that the whole plant matrix may behave differently from an isolated constituent is not new. It echoes debates familiar to anyone who follows cannabinoid research, the question of whether isolated compounds versus full-spectrum preparations produce different physiological effects is central to discussions around the entourage effect in cannabis science. Whether an analogous matrix effect exists for turmeric's curcuminoid and terpene constituents hasn't been thoroughly investigated. It's a gap in the literature that seems worth filling.

Sources

• Complementary Medicines in Australia; Therapeutic Goods Administration (TGA)
• Curcumin: A Review of Its Effects on Human Health, NCBI / National Library of Medicine
• Why Most Published Research Findings on Curcumin Are False (Nelson et al., J Med Chem), NCBI / National Library of Medicine
• Listed Medicines Permitted Indications; Therapeutic Goods Administration (TGA)

, Naomi Ellison, Botanical & phytomedicine writer

]]>